• Mashup Score: 1
    Efficacy of the rehabilitation planning consult for survivors of head and neck cancer: A phase II randomized controlled trial - 7 month(s) ago

    : Survivors of head and neck cancer may have significant lasting impairments and poor access to rehabilitation. To address this, our group developed and evaluated a rehabilitation planning consult (RPC). The RPC is conducted through an initial consultation and a single follow-up session with a rehabilitation professional. During the initial consultation rehabilitation needs are determined and the survivor sets individualized goals and plans. They then implement their plans independently andand are facilitated to evaluate and modify plans as necessary during the follow-up session

    Source: www.redjournal.org
    Categories: Healthcare Professionals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of subatomicdoc
      subatomicdoc

      Efficacy of the rehabilitation planning consult for survivors of head and neck cancer: A phase II randomized controlled trial via @UofTDRO in @IJROBP #hncsm #survonc #radonc https://t.co/O3Wxo41pKV

  • Mashup Score: 0
    Oral Health May Be Linked to Survival in Patients With Head and Neck Squamous Cell Carcinoma - The ASCO Post - 7 month(s) ago

    While survival has improved during the past decades as a result of advances in treatment, head and neck squamous cell carcinoma is the sixth most common malignancy in the world and accounts for about 4% of all U.S. cancer cases. In 2023, an estimated 66,920 patients will be diagnosed with the disease in the United States. The main environmental risk factor for the disease is tobacco use; however, alcohol consumption and testing positive for the human papillomavirus may also increase the risk of developing

    Source: ascopost.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASCOPost
      ASCOPost

      Oral Health May Be Linked to Survival in Patients With Head and Neck Squamous Cell Carcinoma https://t.co/Hx1x32Dpw2 #hncsm #headneckcancer #oncology

  • Mashup Score: 0
    FDA Grants Fast Track Designation to BI 764532 for ES-SCLC and Extrapulmonary NEC - 7 month(s) ago

    The FDA has granted a fast track designation to BI 764532 for the treatment of patients with extensive-stage small cell lung cancer that has progressed following at least 2 prior lines of treatment, and for patients with advanced or metastatic extrapulmonary neuroendocrine carcinoma that has progressed following at least 1 prior line of treatment.

    Source: www.onclive.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncLive
      OncLive

      The investigational DLL3/CD3 IgG-like T-cell engager BI 764532 is currently under investigation in a first-in-human phase 1 trial in DLL3+ SCLC and neuroendocrine carcinoma. @us_fda #hncsm #lcsm https://t.co/9XRWukpBSY https://t.co/ZqZUAPdEFV

  • Mashup Score: 0
    PDS0101 Plus Pembrolizumab Elicits 74% 2-Year OS Rate in ICI-Naïve, HPV16+ HNSCC - 7 month(s) ago

    The addition of PDS0101 to pembrolizumab resulted in a 2-year overall survival rate of 74% in patients with unresectable, recurrent, or metastatic, HPV16-positive head and neck squamous cell carcinoma who were naïve to an immune checkpoint inhibitor.

    Source: www.onclive.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncLive
      OncLive

      The addition of PDS0101 to pembrolizumab resulted in a 2-year overall survival rate of 74% in patients with unresectable, recurrent, or metastatic, HPV16-positive HNSCC who were naïve to an immune checkpoint inhibitor. #hncsm #oncology https://t.co/MsVMGwQyr0

  • Mashup Score: 0
    Daily Adaptive Radiotherapy Delivers Improved Efficacy and Safety Outcomes in HNSCC - 7 month(s) ago

    Daily adaptive radiotherapy with 1-mm planning target volume margins is feasible in patients with head and neck squamous cell carcinoma and was associated with improved dosimetric parameters compared with standard radiotherapy.

    Source: www.onclive.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncLive
      OncLive

      According to preliminary outcomes from the phase 2 DARTBOARD trial, patients in the DART arm received a lower mean ipsilateral parotid dose, at 11.5 Gy vs 16 Gy in the image-guided radiation therapy arm. @DavidSherMD @utswnews @ASTRO_org #ASTRO23 #hncsm https://t.co/uhkFeMdrNp https://t.co/NE8N4suFXe

  • Mashup Score: 0
    FDA Grants Fast Track Designation to BI 764532 for ES-SCLC and Extrapulmonary NEC - 7 month(s) ago

    The FDA has granted a fast track designation to BI 764532 for the treatment of patients with extensive-stage small cell lung cancer that has progressed following at least 2 prior lines of treatment, and for patients with advanced or metastatic extrapulmonary neuroendocrine carcinoma that has progressed following at least 1 prior line of treatment.

    Source: www.onclive.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncLive
      OncLive

      The FDA has granted fast track designation to BI 764532 for the treatment of select patients with ES-SCLC and select patients with advanced or metastatic extrapulmonary NEC. @us_fda #hncsm #lcsm https://t.co/9XRWukq9Iw

Load More